



Attorney's Docket No. 45922/241203 (5865-2)

PATENT

*PH#5*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Gambacorti-Passerini, et al. Confirmation No.: 4010  
Appl. No.: 10/008,377 Group Art Unit: 1642  
Filed: November 15, 2001 Examiner: To be assigned  
For: IMMUNOGENIC ALK PEPTIDES

July 30, 2002

Commissioner for Patents  
Washington, DC 20231

**RECEIVED**

AUG 05 2002

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT  
CITATION UNDER 37 C.F.R. § 1.97**

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

*Patricia L. Chisholm*  
Patricia L. Chisholm  
Registration No. 45,822

**Customer No. 00826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

"Express Mail" Mailing Label Number EL 868644266 US  
Date of Deposit: July 30, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner For Patents, Washington, DC 20231.

*Pamela Lockley*  
Pamela Lockley

Substitute for form 1449A/PTO  
(Revised 10/2001)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number 10/008,377  
Filing Date November 15, 2001  
First Named Inventor Gambacorti-Passerini  
Group Art Unit 1642  
Examiner Name To be assigned  
Attorney Docket Number 45922/241203 (5865-2)

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-5,529,925	06-25-1996	Morris <i>et al.</i>	
	2	US-5,770,421	06-23-1998	Morris <i>et al.</i>	
	3	US-6,174,674 B1	01-16-2001	Morris <i>et al.</i>	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

RECEIVED  
AUG 05 2002  
TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO  
(Revised 10/2001)

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/008,377
Filing Date	November 15, 2001
First Named Inventor	Gambacorti-Passerini
Group Art Unit	1642
Examiner Name	To be assigned
Attorney Docket Number	45922/241203 (5865-2)

### OTHER DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	4	DREXLER, H., <i>et al.</i> , "Pathobiology of NPM-ALK and Variant Fusion Genes in Anaplastic Large Cell Lymphoma and Other Lymphomas," <i>Leukemia</i> , 2000, pp. 1533-1559, Vol. 14, Macmillan Publishers Ltd.	
	5	MORRIS, S., <i>et al.</i> , "Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin's Lymphoma," <i>Science</i> , March 1994, pp. 1281-1284, Vol. 263 (5151), American Association for the Advancement of Science, USA.	
	6	MORRIS, S., <i>et al.</i> , "Sequence Correction," <i>Science</i> , January 1995, pp. 316-317, Vol. 267(5196), American Association for the Advancement of Science, USA.	
	7	PASSONI, L., <i>et al.</i> , "ALK as a Novel Lymphoma-Associated Tumor Antigen: Identification of 2 HLA-A2.1-Restricted CD8 <sup>+</sup> T-cell Epitopes," <i>Blood</i> , March 2002, pp. 2100-2106, Vol. 99(6), The American Society of Hematology, USA.	
	8	PULFORD, K., <i>et al.</i> , "Immune Response to the ALK Oncogenic Tyrosine Kinase in Patients with Anaplastic Large-Cell Lymphoma," <i>Blood</i> , August 2000, pp. 1605-1607, Vol. 96(4), The American Society of Hematology, USA.	
	9	PASSONI, L., <i>et al.</i> , "In Vitro Induction of Primary HLA Class I-Restricted Immune Response Against ALK Kinase," Experimental Lymphoma Therapy, Poster Board No. 509, Session II, Abstract #1459.	

Examiner  
Signature

Date  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.